Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design

Abstract

Artificial intelligence (AI) has emerged as a powerful tool that harnesses anthropomorphic knowledge and provides expedited solutions to complex challenges. Remarkable advancements in AI technology and machine learning present a transformative opportunity in the drug discovery, formulation, and testing of pharmaceutical dosage forms. By utilizing AI algorithms that analyze extensive biological data, including genomics and proteomics, researchers can identify disease-associated targets and predict their interactions with potential drug candidates. This enables a more efficient and targeted approach to drug discovery, thereby increasing the likelihood of successful drug approvals. Furthermore, AI can contribute to reducing development costs by optimizing research and development processes. Machine learning algorithms assist in experimental design and can predict the pharmacokinetics and toxicity of drug candidates. This capability enables the prioritization and optimization of lead compounds, reducing the need for extensive and costly animal testing. Personalized medicine approaches can be facilitated through AI algorithms that analyze real-world patient data, leading to more effective treatment outcomes and improved patient adherence. This comprehensive review explores the wide-ranging applications of AI in drug discovery, drug delivery dosage form designs, process optimization, testing, and pharmacokinetics/pharmacodynamics (PK/PD) studies. This review provides an overview of various AI-based approaches utilized in pharmaceutical technology, highlighting their benefits and drawbacks. Nevertheless, the continued investment in and exploration of AI in the pharmaceutical industry offer exciting prospects for enhancing drug development processes and patient care.

Predictive modeling of skin permeability for molecules: Investigating FDA-approved drug permeability with various AI algorithms

“…Clustering analysis of FDA-approved drugs offers guidance in selecting and optimizing candidates for TDD and provides a unique perspective on skin permeability patterns across therapeutic groups. The study extends from earlier research and holds significant implications for drug development decisions, offering actionable insights for tailoring molecules, prioritizing candidates, and developing targeted and patient-friendly drug delivery systems [ 40 , 41 ]. Furthermore, guided by the principles of the 3Rs (replacement, reduction, and refinement) in animal research, there exists an ethical commitment to diminish the reliance on humans and animals in studies and to explore alternative methodologies, including in vitro and in silico models, for compound testing [ 42 ].…”

Nanomedicine facilitated cell signaling blockade: difficulties and strategies to overcome glioblastoma

“…For better patient outcomes, personalized pharmacokinetic models aid in the optimization of drug doses and treatment plans. 147,148 Machine learning plays a crucial role in predicting the blood-brain barrier (BBB) permeability of chemotherapeutics, expediting drug development specifically for glioblastoma. 149 Experimental validation for theranostic agents crossing the BBB in glioblastoma is time-consuming, often taking a decade with low success rates.…”

The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives

“…Machine learning models can optimize formulation and dosage based on patient characteristics and drug properties. 81…”